BioSpace News Archive

Zavation Medical Products (“Zavation” or the “Company”), an innovative designer and manufacturer of high-quality spinal implants, instruments, MIS procedural kits, and biologics headquartered in Flowood, MS , announced the launch of the Cortical Screw, a screw designed for use in the cortical bone as an extension of the Zavation Spin

With Father’s Day approaching, dermatologists are giving parents two thumbs up for keeping sun protection top of mind for their families.

Medtronic Self-Expanding Venous Stent Demonstrates Favorable Outcomes in Patients with Venous Outflow Obstruction

Technical Safety Services (TSS) announced today that the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) using vaporized hydrogen peroxide (VHP) to decontaminate compatible N95 respirators in the United States for multiple-user reuse by health care personnel.

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020.

The CDC Foundation and the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine today announced a partnership to address the health equity implications of the COVID-19 pandemic. Support for this program is provided by the CDC Foundation’s COVID-19 emergency response fund.

The U.S. Food and Drug Administration today approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference.

miRagen to announce encouraging new preclinical safety and efficacy data for MRG-229 in IPF on June 22nd; and provide an update on the development program during the KOL call

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of its initial public offering of 17,968,750 shares of common stock